Dynamics of Cellular HIV-1 DNA Levels Over 144 Weeks of Darunavir/Ritonavir Monotherapy Versus Triple Therapy in the MONET Trial
Authors:
- Jose R. ArribasJAJose R. Arribas
- Andrew HillAHAndrew Hill
- Yvon van DelftYDYvon van Delft
- 1 February 2013
- journal article
- research article
- Published by Taylor & Francis in HIV Research & Clinical Practice
- Vol. 14 (1) , 45-50
Abstract
Background: In patients receiving combination antiretroviral therapy (ART), switching to monotherapy with ritonavir-boosted darunavir (DRV/r) can maintain plasma HIV-1 RNA suppression with no treatment-emergent drug resistance; effects on cellular HIV-1 DNA burden are less well characterized. Methods: In MONET, patients on stable combination ART for at least 6 months with plasma HIV-1 RNA 10 copies/106 PBMC in the monotherapy arm and 2.59 vs 2.61 log10 copies/106 PBMC in the triple therapy arm, with mean (median) changes of -0.05 (-0.03) and +0.03 (+0.01) log10 copies/106 PBMC in the 2 arms, respectively. Overall baseline HIV-1 DNA levels were higher in patients with nadir CD4 counts P<.05) and in patients who over 144 weeks experienced at least 1 HIV-1 RNA measurement >50 copies/mL (P < .05). Conclusions: In this substudy of the MONET trial, HIV-1 DNA levels remained stable during 144 weeks of either DRV/r monotherapy or triple therapy with DRV/r + 2 NRTIs. In both treatment arms, baseline HIV-1 DNA levels were predicted by the nadir CD4 cell count and predictive of plasma HIV-1 RNA detection during follow-up.Keywords
This publication has 14 references indexed in Scilit:
- Similar Evolution of Cellular HIV-1 DNA Level in Darunavir/Ritonavir Monotherapy versus Triple Therapy in MONOI –ANRS136 Trial over 96 WeeksPLOS ONE, 2012
- The MONET trial: week 144 analysis of the efficacy of darunavir/ritonavir (DRV/r) monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load < 50 HIV‐1 RNA copies/mL at baselineHIV Medicine, 2012
- Relationship Between Residual Plasma Viremia and the Size of HIV Proviral DNA Reservoirs in Infected Individuals Receiving Effective Antiretroviral TherapyThe Journal of Infectious Diseases, 2011
- Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136AIDS, 2010
- A high HIV DNA level in PBMCs at antiretroviral treatment interruption predicts a shorter time to treatment resumption, independently of the CD4 nadirJournal of Medical Virology, 2010
- Impact of 48 week lopinavir/ritonavir monotherapy on blood cell-associated HIV-1-DNA in the MONARK trialJournal of Antimicrobial Chemotherapy, 2010
- Modeling Latently Infected Cell Activation: Viral and Latent Reservoir Persistence, and Viral Blips in HIV-infected Patients on Potent TherapyPLOS Computational Biology, 2009
- LTR real‐time PCR for HIV‐1 DNA quantitation in blood cells for early diagnosis in infants born to seropositive mothers treated in HAART area (ANRS CO 01)Journal of Medical Virology, 2008
- ART Suppresses Plasma HIV-1 RNA to a Stable Set Point Predicted by Pretherapy ViremiaPLOS Pathogens, 2007
- Early Levels of HIV‐1 DNA in Peripheral Blood Mononuclear Cells Are Predictive of Disease Progression Independently of HIV‐1 RNA Levels and CD4+T Cell CountsThe Journal of Infectious Diseases, 2005